Women's Health

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Sequencing for Families with Hereditary Disorders

   Rochester, Minn.

   The purpose of this project will examine the feasibility of offering whole genome sequencing (WGS), and developing a Rapid WGS protocol, for a fetus or neonate with multiple anomalies.

2. A Study to Evaluate Factors in Breast Cancer Screening Among Asian Americans in Olmsted and Surrounding Counties

   Rochester, Minn.

   The purpose of this study is to assess the effect of acculturation, socio-economic status (SES) and place of residence (urban vs. rural) on the level of participation in breast cancer screening programs and on the breast cancer knowledge and beliefs among Asian American women in Olmsted and surrounding counties.

3. A Study Assessing the Effectiveness and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced Triple Negative Breast Cancer

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss without PIK3CA mutation (Study Parts B1 and B2)

4. A Study to Evaluate NT-proBNP Levels in the Prediction of Intrapartum and Postpartum Events in Adult Congenital Heart Disease Patients

   Rochester, Minn.

   The purpose of this study is to characterize the relationship between NT-proBNP levels obtained at time of admission for delivery and subsequent cardiovascular events in ACHD patients, and to describe normative values for NT-proBNP at time of admission for delivery in an uncomplicated obstetric population.

5. A Study to Evaluate Estrogen Receptor (ER) Reactivation Therapy for Breast Cancer

   Rochester, Minn.

   The purpose of this study is to evaluate whether or not treatment with alternating 17B-estradiol / anti-estrogen therapies on a defined 8-week / 16-week schedule will more effectively prevent cancer growth than continuous treatment with either type of therapy in patients with metastatic anti-estrogen-resistant ER+ breast cancer.

    

6. A Study to Evaluate the Venn Ovarian CAncer Liquid Biopsy

   Jacksonville, Fla.

   The primary purpode of this study is to determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the InterVenn Ovarian Cancer Liquid Biopsy among women with ovarian adnexal mass for which a surgery is planned.

7. A Study to Compare Administering Olaparib Concurrently With Radiotherapy vs. Radiotherapy Alone in Treating Patients With Inflammatory Breast Cancer

   Rochester, Minn., La Crosse, Wis., Eau Claire, Wis.

   The purpose of this study is to evaluate how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.

8. A Study to Evaluate Exemestane in Post-Menopausal Women with Non-Small Cell Lung Cancer (NSCLC)

   Albert Lea, Minn., Mankato, Minn.

   This study is being conducted to see if adding Exemestane to the immune checkpoint blockade can slow disease progression in post-menopausal women with non-small cell lung cancer.

9. A Study to Evaluate Women's Birth Experience and Postpartum Mental Health Outcomes

   Rochester, Minn.

   The purpose of this study is to implement a facilitated peer support group for women that have experienced an unexpected birth process in the last 12 months. 

10. A Study to Evaluate TG4050 in Ovarian Carcinoma

    Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    The purpose of this study is to evaluate the safety and tolerability, as well as some activity parameters, of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.